NNMT enzyme inhibition occurs within 24 hours of subcutaneous dosing based on pharmacokinetic modelling, but downstream metabolic effects NAD+ elevation, changes in fat oxidation markers typically require 24 weeks of consistent dosing to manifest in measurable endpoints
Human studies have mainly focused on safety, how the body handles the peptide, and metabolic markers such as IGF-1 and glucose levels, but have not shown strong evidence of weight loss
Furthermore, MGO-treatment affects the tendon biomechanics (reduced stress relaxation, increased yield stress and ultimate failure stress)
This can highlight how the NO-system as a whole may work in each particular circumstance and may interact with BPC 157 or be interacted with BPC 157
Injuries they've seen range from simple to serious, including minor injection site reactions and major hormonal disturbances